RARE | Ultragenyx Pharmaceutical Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	37.80 - 39.24
52 Week Range	29.59 - 60.37
Beta	0.04
Implied Volatility	71.90%
IV Rank	57.54%
Day's Volume	718,625
Average Volume	827,952
Shares Outstanding	93,899,700
Market Cap	3,660,210,306
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-01-31

Valuation
Profitability
Growth
Health
P/E Ratio	-6.20
Forward P/E Ratio	-6.79
EPS	-6.29
1YR Price Target	126.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1,276
Country	USA
Website	RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.

RARE's peers: ADCT, ALLK, ALNY, ARVN, CORT, CVAC, FOLD, HALO, INCY, INSM, JAZZ, MRVI, PBYI, XFOR, TERN, DAWN, PDSB, INZY, MRTX, AMLX, APLS, CRNX, RVMD, KURA, ABOS, UTHR, REGN

*Chart delayed

Analyzing fundamentals for RARE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see RARE Fundamentals page.

Watching at RARE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RARE Technicals page.